Diffuse large B cell lymphoma (DLBCL) is a common and fatal hematological malignancy. Long noncoding RNAs (lncRNAs) have emerged as crucial biomarkers and regulators in many cancers. Novel lncRNA biomarker in DLBCL needs to be investigated badly, as well as its function and molecular mechanism. To further explore, microarray analysis was performed to identify the differentially expressed lncRNAs in DLBCL tissues. To investigate the biological functions of SMAD5-AS1, we performed gain- and loss-of-function experiments in vitro and in vivo. Furthermore, bioinformatics analysis, dual-luciferase reporter assays, Argonaute 2-RNA immunoprecipitation (AGO2-RIP), RNA pull-down assay, quantitative PCR arrays, western blot assay, TOPFlash/FOPFlash reporter assay, and rescue experiments were conducted to explore the underlying mechanisms of competitive endogenous RNAs (ceRNAs). We found that SMAD5-AS1 was down-regulated in DLBCL tissues and cell lines. Functionally, SMAD5-AS1 downregulation promoted cell proliferation in vitro and in vivo, whereas SMAD5-AS1 overexpression could lead to the opposite effects in vitro and in vivo. Bioinformatics analysis and luciferase assays revealed that miR-135b-5p was a direct target of SMAD5-AS1, which was validated by dual-luciferase reporter assays, AGO2-RIP, RNA pull-down assay, and rescue experiments. Also, dual-luciferase reporter assays and rescue experiments demonstrated that miR-135b-5p targeted the adenomatous polyposis coli (APC) gene directly. SMAD5-AS1/miR-135b-5p inhibits the cell proliferation via inactivating the classic Wnt/β-catenin pathway in the form of APC dependency. Our results indicated that SMAD5-AS1 inhibits DLBCL proliferation by sponging miR-135b-5p to up-regulate APC expression and inactivate classic Wnt/β-catenin pathway, suggesting that SMAD5-AS1 may act as a potential biomarker and therapeutic target for DLBCL.

The role of the IRE1α-X-box-binding protein 1 (XBP1) pathway in the insulin-mediated hepatic lipogenic program and associated mechanisms were investigated in this study. We observed that phosphorylation of IRE1α (an upstream activator of XBP1) and splicing (activation) of XBP1 were elevated in the liver of the C57BL/6 mice with insulin resistance/hyperinsulinemia induced by high-fat diet. Treatment of nonobese diabetic mice with insulin activated hepatic XBP1. In cultured primary mouse hepatocytes, prolonged exposure to insulin induced IRE1α phosphorylation and XBP1 splicing significantly in the presence of insulin resistance. Overexpression of the activated XBP1 elevated the promoter activities of the sterol regulatory element-binding protein (SREBP)-1c and fatty acid synthase (FAS) genes. Knockdown of either the IRE1α or XBP1 gene by small interfering RNA prevented the insulin-stimulated promoter activities of both SREBP-1 and FAS genes. In investigating the associated mechanisms, we found a direct interaction between XBP1 and SREBP-1 promoter detected by the chromatin immunoprecipitation assays. Furthermore, the XBP1-mediated stimulation of the FAS promoter was eliminated by knocking down the SREBP-1c gene (Srebf1). Finally, we observed that insulin activation of the IRE1α-XBP1 pathway was prevented by inhibition of mammalian target of rapamycin-dependent protein synthesis. In conclusion, our results show that the IRE1α-XBP1-mediated unfolded protein response pathway is an integrated part of the insulin-induced hepatic lipogenic program and functions at an increased basal level in the presence of insulin resistance and hyperinsulinemia. Besides, the insulin-mediated protein synthesis is tightly connected with the insulin-mediated lipogenic program.

No abstract

No abstract

Estrogen (E2) is reported to regulate skeletal muscle mass and contractile function; whether E2 exerts its effects through estrogen receptor-alpha (ERalpha) or -beta (ERbeta) is unclear. We determined the effect of ERalpha or ERbeta elimination on muscle mass and contractile function in multiple muscles of the lower limb, muscles with different locomotor tasks and proportions of fiber types I and II: soleus (Sol), plantaris (Plan), tibialis anterior (TA), and gastrocnemius (Gast) in mature female mice. To determine E2 elimination effects on muscle, we also used aromatase (Ar) knockout (KO) and wild-type (WT) mice. ERalpha and ArKO body weights were approximately 10 and 20% higher than WT. Although muscle mass tended to show a commensurate increase in both groups, only the TA was significantly larger in ERalpha (P<0.05). Ratios of muscle mass to body mass revealed significantly lower values for Gast and TA in ArKO mice (P<0.05). Tetanic tension (Po) per calculated anatomical cross-sectional area (aCSA) in ERalpha KO was lower in TA and Gast than in WT. Lower Po/aCSA in ERalpha KO Gast and TA was also supported histologically by significantly less Po/fiber areas (P<0.05). ArKO mice also had lower Po/aCSA in Gast and TA compared with WT. ERbeta KO and WT mice were comparable in all measures. Our results support the hypothesis that E2 effects on skeletal muscle are mediated in part via the ERalpha but that E2 effects may be mediated via more than one mechanism or receptor.